本帖最后由 老马 于 2012-1-13 21:20 编辑
( m* T" N' N) t4 _! O" @" V1 g3 t3 U) l: b$ w" J" w- E7 t
爱必妥和阿瓦斯丁的比较2 L; Q6 h' Q! G
' c" |- [# ^) d
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
& \ F+ Y% I2 E- m( Q
7 A7 _' e# v7 G% d9 X9 }
q9 ^7 O, Q0 ]& @% _http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
( h$ F) M$ `. P6 i; s==================================================# U% a) ~/ n5 B i ` |
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)6 k# ?. X- _7 ^# L- ^1 n- q8 z; m
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.! u0 ~. E( V7 `
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.& K2 Q2 e8 }6 @; E; u
|